D-二聚体与新诊断急性淋巴细胞白血病成人患者血栓风险
这项回顾性队列研究纳入芝加哥大学61例连续成人急性淋巴细胞白血病(ALL)患者,评估诊断时D-二聚体水平与100天内静脉或动脉血栓及出血的关系。高D-二聚体(≥4 µg/mL)组100天血栓累积发生率为52.9%,低至中度组(<4 µg/mL)为13.8%,风险比5.04。作者认为诊断时D-二聚体与100天血栓相关,未来研究应结合其他已知危险因素建立风险评估模型。
要点
- 高D-二聚体(≥4 µg/mL)组100天静脉或动脉血栓累积发生率为52.9%。
- 低至中度D-二聚体(<4 µg/mL)组100天血栓累积发生率为13.8%。
- 高D-二聚体组血栓风险比为5.04(95%CI 1.79-14.22)。
核心结论
- 诊断时D-二聚体水平与ALL患者100天静脉或动脉血栓相关。
- 未来研究应结合D-二聚体与其他已知危险因素建立新诊断ALL患者血栓风险评估模型。
研究设计与样本
- 芝加哥大学开展的回顾性队列研究。
- 纳入61例连续成人ALL患者,收集人口学特征、治疗方案、包括D-二聚体在内的基线生物标志物,评估诊断(索引)后100天内静脉或动脉血栓及出血的发生情况。
主要发现
- 高D-二聚体(≥4 µg/mL)组100天静脉或动脉血栓累积发生率为52.9%(95%CI 26.4-73.8)。
- 低至中度D-二聚体(<4 µg/mL)组100天静脉或动脉血栓累积发生率为13.8%(95%CI 5.5-25.7)。
- 高D-二聚体组较低至中度组的风险比为5.04(95%CI 1.79-14.22)。
- 在一系列双变量logistic回归模型中调整体重指数、年龄、性别、门冬酰胺酶治疗、弥散性血管内凝血评分、初始血小板水平和ALL免疫表型后,D-二聚体与血栓的关联仍然存在。
关键数值与推荐
- 高D-二聚体定义为≥4 µg/mL。
- 低至中度D-二聚体定义为<4 µg/mL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with acute lymphoblastic leukemia (ALL) are at increased risk of thrombotic and/or bleeding events during early chemotherapy, especially when receiving asparaginase. D-dimer is a marker of fibrinolysis that has been associated with thrombotic risk in solid cancers and acute myeloid leukemia; however, to date, no ALL-based study has assessed D-dimer level and risk for thrombosis. We sought to examine D-dimer as a biomarker for risk of thrombosis or bleeding during ALL treatment in a retrospective cohort study at The University of Chicago. We identified 61 consecutive adult patients with ALL, gathering demographic characteristics, treatment regimens, initial biomarkers including D-dimer, and assessing occurrence of venous or arterial thrombosis and bleeding in the first 100 days after diagnosis (index). The 100-day cumulative incidence (95% confidence interval [CI]) of venous or arterial thrombosis in patients with high D-dimer (≥4 µg/mL) was 52.9% (95% CI, 26.4-73.8) compared with 13.8% (95% CI, 5.5-25.7) in patients with low to moderate D-dimer (<4 µg/mL), corresponding with a hazard ratio of 5.04 (95% CI, 1.79-14.22). When testing for potential confounders in a series of bivariate logistic regression models, the association between D-dimer and thrombosis remained after adjusting for body mass index, age, sex, asparaginase treatment, disseminated intravascular coagulation score, initial platelet level, and ALL phenotype. In conclusion, D-dimer levels at ALL diagnosis are associated with venous or arterial thrombosis at 100 days. Future studies should include D-dimer collated with other known risk factors to build a risk assessment model for thrombosis in patients with newly diagnosed ALL.
引用
- Anderson DR, Stock W, Karrison TG, et al. D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia. Blood Adv. 2022. PMID: 35728059. doi:10.1182/bloodadvances.2022007699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。